Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-07-07 4:35 pm Sale | 2023-06-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 5,747,184 4.900% | -1,957,010 (-25.40%) | Filing History |
| 2023-02-14 12:40 pm Purchase | 2022-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | T. Rowe Price Investment Management, Inc. | 5,842,660 5.300% | 5,842,660 (New Position) | Filing History |
| 2023-02-14 12:38 pm Sale | 2022-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | T. Rowe Price Associates, Inc. | 2,749,542 2.500% | -2,557,944 (-48.20%) | Filing History |
| 2023-02-14 09:36 am Purchase | 2022-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | Avoro Capital Advisors LLC | 10,625,000 9.600% | 2,069,445 (+24.19%) | Filing History |
| 2023-02-09 11:07 am Purchase | 2022-12-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | The Vanguard Group | 9,212,491 8.330% | 1,295,392 (+16.36%) | Filing History |
| 2023-02-06 2:49 pm Sale | 2022-12-30 | 13G | Apellis Pharmaceuticals, Inc. APLS | Wellington Management Group LLP | 8,820,398 7.980% | -3,657,855 (-29.31%) | Filing History |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 7,704,194 7.000% | 1,838,482 (+31.34%) | Filing History |
| 2022-02-14 4:05 pm Purchase | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | Morningside Venture Investments Limited | 12,806,342 13.200% | 250,000 (+1.99%) | Filing History |
| 2022-02-14 4:04 pm Sale | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | HHLR ADVISORS LTD. | 0 0.000% | -5,028,289 (Position Closed) | Filing History |
| 2022-02-14 2:34 pm Purchase | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | T. Rowe Price Associates, Inc. | 5,307,486 5.400% | 5,307,486 (New Position) | Filing History |
| 2022-02-11 10:04 am Purchase | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | Avoro Capital Advisors LLC | 8,555,555 8.900% | 8,555,555 (New Position) | Filing History |
| 2022-02-09 3:24 pm Purchase | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | The Vanguard Group | 7,917,099 8.140% | 2,375,274 (+42.86%) | Filing History |
| 2022-02-04 09:15 am Purchase | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | Wellington Management Group LLP | 12,478,253 12.830% | 1,900,333 (+17.97%) | Filing History |
| 2022-02-03 4:41 pm Sale | 2021-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 5,865,712 6.100% | -149,236 (-2.48%) | Filing History |
| 2021-02-16 4:17 pm Purchase | 2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | Morningside Venture Investments Limited | 12,556,342 15.800% | 540,540 (+4.50%) | Filing History |
| 2021-02-16 4:09 pm Purchase | 2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | HHLR ADVISORS LTD. | 5,028,289 6.600% | 350,000 (+7.48%) | Filing History |
| 2021-02-10 10:30 am Purchase | 2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | The Vanguard Group | 5,541,825 7.320% | 5,541,825 (New Position) | Filing History |
| 2021-02-05 07:51 am Purchase | 2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | BlackRock Inc. BLK | 6,014,948 7.900% | 1,257,443 (+26.43%) | Filing History |
| 2021-02-03 1:33 pm Purchase | 2020-12-31 | 13G | Apellis Pharmaceuticals, Inc. APLS | Wellington Management Group LLP | 10,577,920 13.970% | 295,290 (+2.87%) | Filing History |